Last reviewed · How we verify

Candesartan cilexetil/Amlodipine besylate

HK inno.N Corporation · FDA-approved active Small molecule

Candesartan cilexetil/Amlodipine besylate is a Angiotensin II receptor blocker / Calcium channel blocker combination Small molecule drug developed by HK inno.N Corporation. It is currently FDA-approved for Hypertension (high blood pressure). Also known as: Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg.

This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance.

This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance. Used for Hypertension (high blood pressure).

At a glance

Generic nameCandesartan cilexetil/Amlodipine besylate
Also known asCandesartan cilexetil/Amlodipine besylate 8 mg/5 mg
SponsorHK inno.N Corporation
Drug classAngiotensin II receptor blocker / Calcium channel blocker combination
TargetAT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Candesartan cilexetil is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Amlodipine besylate is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation. Together, these complementary mechanisms provide additive blood pressure reduction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Candesartan cilexetil/Amlodipine besylate

What is Candesartan cilexetil/Amlodipine besylate?

Candesartan cilexetil/Amlodipine besylate is a Angiotensin II receptor blocker / Calcium channel blocker combination drug developed by HK inno.N Corporation, indicated for Hypertension (high blood pressure).

How does Candesartan cilexetil/Amlodipine besylate work?

This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through vasodilation and decreased vascular resistance.

What is Candesartan cilexetil/Amlodipine besylate used for?

Candesartan cilexetil/Amlodipine besylate is indicated for Hypertension (high blood pressure).

Who makes Candesartan cilexetil/Amlodipine besylate?

Candesartan cilexetil/Amlodipine besylate is developed and marketed by HK inno.N Corporation (see full HK inno.N Corporation pipeline at /company/hk-inno-n-corporation).

Is Candesartan cilexetil/Amlodipine besylate also known as anything else?

Candesartan cilexetil/Amlodipine besylate is also known as Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg.

What drug class is Candesartan cilexetil/Amlodipine besylate in?

Candesartan cilexetil/Amlodipine besylate belongs to the Angiotensin II receptor blocker / Calcium channel blocker combination class. See all Angiotensin II receptor blocker / Calcium channel blocker combination drugs at /class/angiotensin-ii-receptor-blocker-calcium-channel-blocker-combination.

What development phase is Candesartan cilexetil/Amlodipine besylate in?

Candesartan cilexetil/Amlodipine besylate is FDA-approved (marketed).

What are the side effects of Candesartan cilexetil/Amlodipine besylate?

Common side effects of Candesartan cilexetil/Amlodipine besylate include Dizziness, Headache, Peripheral edema, Fatigue, Hyperkalemia (with ARB component).

What does Candesartan cilexetil/Amlodipine besylate target?

Candesartan cilexetil/Amlodipine besylate targets AT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel and is a Angiotensin II receptor blocker / Calcium channel blocker combination.

Related